JNJ

192.08

-0.38%↓

ABT

126.36

-1.14%↓

MDT

94.19

-1.71%↓

VEEV

291.41

+0.69%↑

A

147.65

+1.19%↑

JNJ

192.08

-0.38%↓

ABT

126.36

-1.14%↓

MDT

94.19

-1.71%↓

VEEV

291.41

+0.69%↑

A

147.65

+1.19%↑

JNJ

192.08

-0.38%↓

ABT

126.36

-1.14%↓

MDT

94.19

-1.71%↓

VEEV

291.41

+0.69%↑

A

147.65

+1.19%↑

JNJ

192.08

-0.38%↓

ABT

126.36

-1.14%↓

MDT

94.19

-1.71%↓

VEEV

291.41

+0.69%↑

A

147.65

+1.19%↑

JNJ

192.08

-0.38%↓

ABT

126.36

-1.14%↓

MDT

94.19

-1.71%↓

VEEV

291.41

+0.69%↑

A

147.65

+1.19%↑

Search

Apellis Pharmaceuticals Inc

Gesloten

SectorGezondheidszorg

28.6 1.89

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

28.02

Max

28.89

Belangrijke statistieken

By Trading Economics

Inkomsten

50M

-42M

Verkoop

12M

178M

Winstmarge

-23.615

Werknemers

705

EBITDA

50M

-30M

Aanbevelingen

By TipRanks

Aanbevelingen

Buy

12 Maanden Prognose

+28.14% upside

Dividenden

By Dow Jones

Volgende Winsten

30 okt 2025

Marktinformatie

By TradingEconomics

Marktkapitalisatie

1.2B

3.6B

Vorige openingsprijs

26.71

Vorige sluitingsprijs

28.6

Nieuwssentiment

By Acuity

34%

66%

108 / 371 Rangschikking in Healthcare

Apellis Pharmaceuticals Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

23 okt 2025, 20:49 UTC

Winsten

Correction to Thermo Fisher Article on Oct. 22

23 okt 2025, 23:51 UTC

Marktinformatie

WiseTech Bull Cheered by DSV's Freight Volumes -- Market Talk

23 okt 2025, 23:49 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

23 okt 2025, 23:49 UTC

Marktinformatie

Nikkei May Rise on Hopes for Easing U.S.-China Tensions -- Market Talk

23 okt 2025, 23:37 UTC

Marktinformatie

Gold Falls on Likely Further Unwinding of Long Positions -- Market Talk

23 okt 2025, 22:58 UTC

Marktinformatie

Global Energy Roundup: Market Talk

23 okt 2025, 22:57 UTC

Marktinformatie

Woodside's Deal With Williams Eases Risks on Louisiana LNG Project -- Market Talk

23 okt 2025, 22:49 UTC

Acquisities, Fusies, Overnames

How Trump Sparked a New Era of State Capitalism -2-

23 okt 2025, 22:49 UTC

Acquisities, Fusies, Overnames

How Trump Sparked a New Era of State Capitalism -- Barrons.com

23 okt 2025, 22:17 UTC

Winsten

Intel Shows Progress in First Earnings Report Since U.S. Investment -- 3rd Update

23 okt 2025, 21:41 UTC

Winsten

Intel Shows Progress in First Earnings Report Since U.S. Investment -- 2nd Update

23 okt 2025, 21:05 UTC

Winsten

Valero Earnings Show Why Refiners Are Energy's Big Winners This Year -- Barrons.com

23 okt 2025, 20:50 UTC

Marktinformatie
Winsten

Tech, Media & Telecom Roundup: Market Talk

23 okt 2025, 20:50 UTC

Marktinformatie
Winsten

Auto & Transport Roundup: Market Talk

23 okt 2025, 20:50 UTC

Marktinformatie

Basic Materials Roundup: Market Talk

23 okt 2025, 20:35 UTC

Winsten

These Stocks Moved the Most Today: Tesla, IBM, D-Wave Quantum, Dow Inc., Molina Healthcare, Las Vegas Sands, Southwest, and More -- Barrons.com

23 okt 2025, 20:28 UTC

Winsten

Intel Shows Progress in First Earnings Report Since U.S. Investment -- Update

23 okt 2025, 20:15 UTC

Marktinformatie
Winsten

Global Commodities Roundup: Market Talk

23 okt 2025, 20:10 UTC

Winsten

Newmont Mining 3Q Adj EPS $1.71

23 okt 2025, 20:10 UTC

Winsten

Newmont Mining 3Q Sales $5.52B

23 okt 2025, 20:10 UTC

Winsten

Newmont Mining 3Q EPS $1.67

23 okt 2025, 20:09 UTC

Winsten

Intel Stock Rises After Strong Earnings. CFO Says Chip Demand Will Outpace Supply Into Next Year. -- Barrons.com

23 okt 2025, 20:07 UTC

Marktinformatie
Winsten

Global Equities Roundup: Market Talk

23 okt 2025, 20:07 UTC

Marktinformatie
Winsten

Ford Scrambles to Mitigate New Costs from Supplier Fire -- Market Talk

23 okt 2025, 20:07 UTC

Winsten

Blackstone Looks to IPOs for Investment Exits -- Update

23 okt 2025, 20:05 UTC

Winsten

Intel 3Q Gross Margin 38.2% >INTC

23 okt 2025, 20:04 UTC

Winsten

Intel CFO: 'Current Demand Is Outpacing Supply, a Trend We Expect Will Persist Into 2026' >INTC

23 okt 2025, 20:04 UTC

Winsten

Intel Shows Progress in First Earnings Report Since U.S. Investment -- WSJ

23 okt 2025, 20:04 UTC

Winsten

Intel: 4Q Guidance Excludes Altera >INTC

23 okt 2025, 20:04 UTC

Winsten

Intel Sees 4Q Adj EPS 8c >INTC

Peer Vergelijking

Prijswijziging

Apellis Pharmaceuticals Inc Prognose

Koersdoel

By TipRanks

28.14% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 36.06 USD  28.14%

Hoogste 60 USD

Laagste 18 USD

Gebaseerd op 17 Wall Street-analisten die 12-maands prijsdoelen bieden voor Apellis Pharmaceuticals Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Buy

17 ratings

10

Buy

6

Hold

1

Sell

Sentiment

By Acuity

108 / 371 Rangschikking in Gezondheidszorg

Nieuwssentiment

Bullish Bewijs

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Onder gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Apellis Pharmaceuticals Inc

Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA). The company also develops APL-3007, a small interfering RNA, or siRNA, which is in a Phase 1 clinical trial, as well as an oral complement inhibitor that is in preclinical development. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) for development and commercialization of pegcetacoplan; and a collaboration with Beam Therapeutics Inc. focused on the use of Beam's base editing technology to discover new treatments for complement-driven diseases. The company was incorporated in 2009 and is based in Waltham, Massachusetts.
help-icon Live chat